The Imunon, Inc. (IMNN) share price is expected to increase by 821.05% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered IMNN. Price targets range from $8 at the low end to $14 at the high end. The current analyst consensus for IMNN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
IMNN is a stock in Health Care which has been forecasted to be worth $10.5 as an average. On the higher end, the forecast price is $14 USD by Emily Bodnar from HC Wainwright & Co. and on the lower end IMNN is forecasted to be $8 by from .
These are the latest 20 analyst ratings of IMNN.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Emily Bodnar HC Wainwright & Co. | Buy | $14 | Reiterates | Aug 15, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $14 | Maintains | Aug 5, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $12 | Maintains | May 14, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $13 | Maintains | Apr 1, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Mar 13, 2024 |
Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Sep 15, 2023 |
Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 11, 2023 |
Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | May 12, 2023 |
James Molloy Alliance Global Partners | Buy | $15 | Initiates | Oct 13, 2022 |
HC Wainwright & Co. | Buy | Initiates | Apr 13, 2022 |
When did it IPO
N/A
Staff Count
33
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Stacy R. Lindborg Ph.D.
Market Cap
$15.7M
In 2023, IMNN generated $0 in revenue, which was a decrease of -100.00% from the previous year. This can be seen as a signal that IMNN's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.